…
Hydrix Limited, together with its subsidiaries, operates as a product design and engineering company in Australia, Europe, North America, New Zealand, the United States, and Singapore. It operates through three segments: Hydrix Services, Hydrix Medical, and Hydrix Ventures. The company offers product design and development consulting services comprising safety critical control systems engineering, software, electronics, mechanical, human factors, and industrial design services; and product consulting services consisting of engineering design, development, prototyping, manufacturer management, and certification process management services. It also distributes remote cardiac monitoring technologies, including a cloud-based AI-driven remote cardiac patient monitoring and data management software. In addition, the company manages a portfolio of venture investments in early-stage medtech companies. It serves the medtech, cardiac health, defence, and industrial market sectors. The company was formerly known as Panorama Synergy Limited and changed its name to Hydrix Limited in November 2018. Hydrix Limited was incorporated in 1993 and is headquartered in Mulgrave, Australia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
HYDRIX Ltd (ASX: HYD) is an Australian-listed company for which publicly available disclosures are limited, so its core operations, products and financial position are not well documented in major reporting sources. Given the sparse information, potential long-term growth drivers could include securing commercial contracts, scaling operations within its sector and benefiting from broader industry trends, and investors may find the company of interest if management provides clearer disclosure and demonstrates sustainable revenue growth.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Income before tax | -6.72M | -2.92M | -9.56M | -0.40M | -5.55M |
| Net income | -6.72M | -2.92M | -9.56M | -0.40M | -5.55M |
| Selling general administrative | - | 9.17M | 10.96M | 12.08M | 11.31M |
| Selling and marketing expenses | - | 0.16M | 0.27M | 0.35M | 0.25M |
| Gross profit | -0.34M | 9.53M | 9.79M | 13.16M | 10.31M |
| Reconciled depreciation | - | 0.76M | 0.94M | 1.32M | 1.14M |
| Ebit | -2.85M | -1.81M | -8.86M | 0.29M | -5.41M |
| Ebitda | -2.32M | -1.40M | -7.92M | 1.61M | -4.26M |
| Depreciation and amortization | 0.53M | 0.41M | 0.94M | 1.32M | 1.14M |
| Operating income | -2.85M | 0.21M | -4.75M | -3.88M | -5.85M |
| Other operating expenses | 12.60M | 9.89M | 15.37M | -10.53M | -11.92M |
| Interest expense | 1.22M | 1.05M | 0.70M | 0.17M | 0.14M |
| Tax provision | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Interest income | - | 0.02M | 0.02M | 0.21M | 0.01M |
| Net interest income | - | -1.03M | -0.68M | -0.41M | -0.45M |
| Income tax expense | - | - | -3.23M | 4.68M | 0.72M |
| Total revenue | 9.74M | 10.09M | 10.61M | 13.18M | 10.32M |
| Total operating expenses | 2.52M | 9.32M | 15.35M | 17.13M | 15.98M |
| Cost of revenue | 10.08M | 0.56M | 0.82M | 0.02M | 0.01M |
| Total other income expense net | -3.86M | -3.13M | -4.80M | 3.99M | 0.58M |
| Net income from continuing ops | - | -3.65M | -9.56M | -0.40M | -5.55M |
| Net income applicable to common shares | - | -3.81M | -9.56M | -0.40M | -5.55M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Total assets | 6.09M | 8.35M | 8.69M | 14.58M | 15.94M |
| Intangible assets | - | 0.53M | - | 3.44M | 4.56M |
| Other current assets | 0.21M | 0.24M | 0.26M | 0.35M | 0.85M |
| Total liab | 14.24M | 14.39M | 12.05M | 8.22M | 12.66M |
| Total stockholder equity | -8.15M | -6.04M | -3.36M | 6.35M | 3.28M |
| Other current liab | 1.05M | 1.53M | 3.09M | 0.71M | 4.42M |
| Common stock | 104.28M | 102.41M | 102.13M | 102.13M | 98.82M |
| Capital stock | - | - | - | 102.13M | 98.82M |
| Retained earnings | -115.88M | -108.51M | -105.84M | -96.45M | -96.98M |
| Other liab | - | - | - | 0.36M | 0.33M |
| Good will | - | - | - | - | 0.00M |
| Other assets | - | - | - | 0.08M | 0.50M |
| Cash | 2.96M | 0.30M | 0.91M | 1.15M | 1.94M |
| Cash and equivalents | - | - | - | 1.15M | 1.94M |
| Total current liabilities | 13.29M | 11.94M | 6.97M | 5.36M | 8.72M |
| Current deferred revenue | 0.52M | - | 0.50M | 2.11M | 2.14M |
| Net debt | 5.39M | 7.69M | 6.69M | 3.58M | 3.46M |
| Short term debt | 7.64M | 5.89M | 2.97M | 2.22M | 1.79M |
| Short long term debt | - | - | - | 1.37M | 1.04M |
| Short long term debt total | 8.35M | 7.98M | 7.61M | 4.73M | 5.40M |
| Other stockholder equity | - | - | - | -5.67M | -1.85M |
| Property plant equipment | - | - | - | 1.46M | 1.99M |
| Total current assets | 4.72M | 2.66M | 2.79M | 4.28M | 5.06M |
| Long term investments | - | - | - | 5.32M | 4.26M |
| Net tangible assets | - | - | - | 2.91M | -1.28M |
| Short term investments | - | - | - | -0.42M | -0.42M |
| Net receivables | 1.56M | 2.13M | 1.61M | 2.43M | 2.01M |
| Long term debt | - | - | - | 1.00M | 1.25M |
| Inventory | - | 0.00M | 0.00M | 0.02M | 0.01M |
| Accounts payable | 4.08M | 4.52M | 0.42M | 0.31M | 0.37M |
| Accumulated other comprehensive income | 3.45M | 0.06M | 0.35M | 0.68M | 1.43M |
| Non currrent assets other | 0.27M | 0.53M | 1.05M | 0.08M | 0.07M |
| Non current assets total | 1.37M | 5.69M | 5.90M | 10.30M | 10.88M |
| Capital lease obligations | - | - | - | 2.36M | 3.11M |
| Long term debt total | - | - | - | 2.51M | 3.61M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Investments | - | -0.05M | -0.05M | -0.21M | -0.15M |
| Change to liabilities | - | - | - | -0.72M | -0.27M |
| Total cashflows from investing activities | 0.15M | -0.05M | -0.05M | -0.21M | -0.31M |
| Net borrowings | - | 1.05M | 2.98M | -0.42M | -0.47M |
| Total cash from financing activities | 5.00M | -0.04M | 1.71M | 2.16M | 1.72M |
| Change to operating activities | - | - | - | -0.13M | -0.11M |
| Net income | -6.72M | -2.92M | -9.56M | -0.40M | -5.55M |
| Change in cash | 2.66M | -0.62M | -0.24M | -0.79M | -4.71M |
| Begin period cash flow | 0.30M | 0.91M | 1.15M | 1.94M | 6.65M |
| End period cash flow | 2.96M | 0.30M | 0.91M | 1.15M | 1.94M |
| Total cash from operating activities | -2.48M | -0.53M | -1.89M | -2.73M | -6.12M |
| Issuance of capital stock | - | - | - | 3.37M | 2.88M |
| Depreciation | 0.53M | 0.41M | 0.94M | 1.19M | 1.04M |
| Other cashflows from investing activities | 0.20M | -0.05M | -0.04M | - | -0.24M |
| Dividends paid | - | - | - | -0.39M | -0.24M |
| Change to inventory | - | - | 0.02M | -0.01M | -0.00M |
| Change to account receivables | - | - | 1.07M | -0.40M | -1.42M |
| Sale purchase of stock | - | - | - | -0.40M | -0.23M |
| Other cashflows from financing activities | -0.48M | -0.41M | -0.50M | 0.06M | -0.51M |
| Change to netincome | - | - | - | -2.39M | 0.09M |
| Capital expenditures | 0.03M | 0.01M | 0.01M | 0.20M | 0.17M |
| Change in working capital | - | 0.07M | 2.27M | -0.41M | -1.42M |
| Stock based compensation | - | 0.05M | -0.13M | 0.26M | 0.47M |
| Other non cash items | 3.71M | 1.93M | 4.46M | -3.53M | -1.62M |
| Free cash flow | -2.51M | -0.54M | -1.91M | -2.93M | -6.29M |
Sector: Technology Industry: Scientific & Technical Instruments
|
Stock Name
|
Change
(AUD) |
Price
(AUD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| HYD HYDRIX Ltd |
- -% |
0.00 | - | 7.96 | 0.30 | 1.25 | 0.93 | -2.67 |
| CDA Codan Ltd |
-1.83 3.16% |
56.07 | 58.46 | 36.76 | 11.69 | 17.92 | 12.47 | 38.25 |
| CAT Catapult Group International Ltd |
-0.05 1.31% |
3.76 | - | 49.02 | 8.40 | 3.56 | 5.03 | 46.83 |
| OIL Optiscan Imaging Ltd |
0.00 1.29% |
0.16 | - | 10.82 | 44.85 | 8.28 | 320.51 | -12.11 |
| IKE Ikegps Group Ltd |
- -% |
0.70 | - | - | 4.96 | 6.72 | 5.61 | -3.62 |
Hydrix Limited, together with its subsidiaries, operates as a product design and engineering company in Australia, Europe, North America, New Zealand, the United States, and Singapore. It operates through three segments: Hydrix Services, Hydrix Medical, and Hydrix Ventures. The company offers product design and development consulting services comprising safety critical control systems engineering, software, electronics, mechanical, human factors, and industrial design services; and product consulting services consisting of engineering design, development, prototyping, manufacturer management, and certification process management services. It also distributes remote cardiac monitoring technologies, including a cloud-based AI-driven remote cardiac patient monitoring and data management software. In addition, the company manages a portfolio of venture investments in early-stage medtech companies. It serves the medtech, cardiac health, defence, and industrial market sectors. The company was formerly known as Panorama Synergy Limited and changed its name to Hydrix Limited in November 2018. Hydrix Limited was incorporated in 1993 and is headquartered in Mulgrave, Australia.
| Name | Title | Year Born |
|---|---|---|
| Mr. Gavin Coote | Exec. Chairman | NA |
| Mr. Mark Langham | Group Financial Controller | NA |
| Ms. Vickie Edwards | Director Sales & Operations | NA |
| Ms. Alyn Tai L.L.B., LLB (Hons) | Corp. Counsel & Company Sec. | NA |
| Mr. Alan Morris | Group Marketing Director | NA |
| Robert Brierley | Global Director of Human Resource | NA |
| Dr. John Bumgarner | Chief Research Officer | NA |
| Mr. Peter R. Lewis A.M. | Exec. VP of Bus. Devel. | NA |
| Mr. Paul Kelly | GM of Cardiac Products & Member of Medical Advisory Board | NA |
| Dr. Stewart James Washer B.Sc., BSc (Hons), Ph.D. | Specialist Biosciences Adviser & Member of Advisory Board | 1970 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.